Prevalence, incidence, and season distribution of MOG antibody-associated disease in the province of Verona, Italy.


Journal

Multiple sclerosis and related disorders
ISSN: 2211-0356
Titre abrégé: Mult Scler Relat Disord
Pays: Netherlands
ID NLM: 101580247

Informations de publication

Date de publication:
Jul 2022
Historique:
received: 03 03 2022
revised: 16 04 2022
accepted: 13 05 2022
pubmed: 15 6 2022
medline: 29 6 2022
entrez: 14 6 2022
Statut: ppublish

Résumé

Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD) is a demyelinating disorder of the central nervous system whose epidemiological features are still unclear. We report current prevalence and incidence rates of MOGAD in the population of Verona province, Italy, and the seasonal distribution of disease onset. MOGAD patients residing in Verona province were included through the consultation of a database from our Neuropathology Laboratory. Provincial prevalence was determined on 2021/1/1 (resident population: 922,291 people) and incidence rates between 2016/1/1 and 2021/1/1 were calculated from all cases, divided by the total number of person-years at risk. We also examined the distribution of attacks by month and season. We included 23 prevalent MOGAD cases (13 females), with a median age at onset of 36 years (range 5-69). Prevalence rate was 2.5/100,000 (95% CI 1.7-3.7). 22 incident cases were collected, with an incidence rate of 4.8/million person-years (95% CI 3.1-7.2). Among the 23 prevalent patients, disease onset was more frequent in December (4 cases), February, May, and September (3 cases/month), with a global autumn-winter predominance (September-February) of 15 cases (65%), irrespective of the clinical manifestation. This is the first study on an Italian population to report MOGAD prevalence and incidence rates; they are higher than the estimates for aquaporin-4-seropositive neuromyelitis optica spectrum disorder in the Caucasian population, but far lower than Multiple Sclerosis. An autumn-winter predominance of disease onset is suggested, and it could be related to environmental factors that should be ascertained, although validation in larger cohorts is mandatory.

Sections du résumé

BACKGROUND BACKGROUND
Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD) is a demyelinating disorder of the central nervous system whose epidemiological features are still unclear. We report current prevalence and incidence rates of MOGAD in the population of Verona province, Italy, and the seasonal distribution of disease onset.
METHODS METHODS
MOGAD patients residing in Verona province were included through the consultation of a database from our Neuropathology Laboratory. Provincial prevalence was determined on 2021/1/1 (resident population: 922,291 people) and incidence rates between 2016/1/1 and 2021/1/1 were calculated from all cases, divided by the total number of person-years at risk. We also examined the distribution of attacks by month and season.
RESULTS RESULTS
We included 23 prevalent MOGAD cases (13 females), with a median age at onset of 36 years (range 5-69). Prevalence rate was 2.5/100,000 (95% CI 1.7-3.7). 22 incident cases were collected, with an incidence rate of 4.8/million person-years (95% CI 3.1-7.2). Among the 23 prevalent patients, disease onset was more frequent in December (4 cases), February, May, and September (3 cases/month), with a global autumn-winter predominance (September-February) of 15 cases (65%), irrespective of the clinical manifestation.
CONCLUSIONS CONCLUSIONS
This is the first study on an Italian population to report MOGAD prevalence and incidence rates; they are higher than the estimates for aquaporin-4-seropositive neuromyelitis optica spectrum disorder in the Caucasian population, but far lower than Multiple Sclerosis. An autumn-winter predominance of disease onset is suggested, and it could be related to environmental factors that should be ascertained, although validation in larger cohorts is mandatory.

Identifiants

pubmed: 35700669
pii: S2211-0348(22)00396-0
doi: 10.1016/j.msard.2022.103884
pii:
doi:

Substances chimiques

Aquaporin 4 0
Autoantibodies 0
Myelin-Oligodendrocyte Glycoprotein 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

103884

Informations de copyright

Copyright © 2022. Published by Elsevier B.V.

Auteurs

Riccardo Orlandi (R)

Neurology Unit, Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Piazzale, L.A. Scuro 10, Verona 37134, Italy. Electronic address: riccardo.orlandi@univr.it.

Sara Mariotto (S)

Neurology Unit, Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Piazzale, L.A. Scuro 10, Verona 37134, Italy.

Alberto Gajofatto (A)

Neurology Unit, Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Piazzale, L.A. Scuro 10, Verona 37134, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH